Please assess the completion status of the following clinical trial:

Trial Title: Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Active rheumatoid arthritis~* Inadequate response to stably dosed methotrexate~Exclusion Criteria:~* Current therapy with any DMARD or biologic other than methotrexate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CP 690,550 1 mg BID (Type: EXPERIMENTAL): None
- CP 690,550 10 mg BID (Type: EXPERIMENTAL): None
- CP 690,550 15 mg (Type: EXPERIMENTAL): None
- CP 690,550 3 mg BID (Type: EXPERIMENTAL): None
- CP 690,550 5 mg BID (Type: EXPERIMENTAL): None
- CP-690,550 20 mg QD (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): Dummy tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).